BEAM - Bluebird Bio drives gene therapy stocks higher after FDA review

A group of biotechs focused on gene therapy candidates surged on Tuesday after the FDA posted a favorable review on a ?-thalassemia candidate developed by commercial-stage company Bluebird bio (NASDAQ:BLUE) ahead of an AdCom meeting later this week. The data for the marketing application of one-time gene therapy beti-cel “support the effectiveness” of the drug for the targeted indication with a “clinically meaningful benefit,” the FDA reviewers wrote. Despite safety concerns cited for data supporting its second gene therapy candidate eli-cel for cerebral adrenoleukodystrophy, Bluebird bio (BLUE) has posted its best intraday gain since 2014. Other notable gainers in the gene therapy space include: Homology Medicines (FIXX), Selecta Biosciences (SELB), Sio Gene Therapies (SIOX), Taysha Gene Therapies (TSHA), Iovance Biotherapeutics (IOVA),  uniQure N.V. (QURE), and Voyager Therapeutics (VYGR). Gene editing companies such as Precision BioSciences (DTIL), Sangamo Therapeutics (SGMO), Verve Therapeutics (VERV), Editas Medicine (EDIT) and Beam Therapeutics (BEAM) have

For further details see:

Bluebird Bio drives gene therapy stocks higher after FDA review